Avian transgenesis via site-directed integration

通过定点整合进行鸟类转基因

• 批准号: 7056763
• 负责人: Alex Jordan Harvey
• 金额: $ 33.68万
• 依托单位: SYNAGEVA BIOPHARMA CORPORATION
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-01-15 至 2008-04-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7056763
• 关键词: biotechnology; chick embryo; chickens; gene delivery system; gene targeting; genetically modified animals; integrase; method development; protein biosynthesis; protein structure function; transfection

DESCRIPTION (provided by applicant): This Phase II SBIR project describes a novel method to create transgenic poultry that will produce biopharmaceutical proteins in their eggs. Chickens are able to produce large amounts of protein in their eggs at relatively low cost. We seek to harness this capability to synthesize pharmaceutical proteins, such as humanized monoclonal antibodies, that are needed in large amounts. The efficiency of transgenesis in chickens, particularly with large transgenes, is exceedingly low. We propose here to overcome this hurdle by the use of integration-promoting enzymes which are able to recombine specific DMA sequences with a high efficiency. In Phase II of this project, the integration-promoting enzymes will be used to insert transgenes encoding pharmaceutical proteins, and driven by egg white specific promoters, into the genome of chickens. This novel technology will expedite the creation of chickens that can produce Pharmaceuticals, thereby facilitating drug development, enhancing clinical trials and lowering the cost of Pharmaceuticals.

描述（由申请人提供）：该二期SBIR项目描述了一种创造转基因家禽的新方法，该转基因家禽将在其蛋中产生生物制药蛋白。鸡能够以相对较低的成本在鸡蛋中产生大量蛋白质。我们寻求利用这种能力来合成大量需要的药用蛋白，如人源化单克隆抗体。